Cytiva disclosed plans to complete $1.6 billion in expansions across the US, Europe, and Asia, to meet rising demand for biopharma manufacturing capabilities and promote in-region production. Concurrently, Mount Sinai's AI Small Molecule Drug Discovery Center launched to address inefficiencies in traditional drug discovery by fostering computational and AI-driven approaches. These initiatives exemplify industry's dual focus on scaling manufacturing infrastructure while integrating AI technologies to accelerate novel therapeutic development.